Aeterna to present two novel anticancer compounds at Bio Partnering North America conference

Feb 23 2011

Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company") today announced that its Vice President, Alliance Management and Intellectual Property, Eckhard Guenther, Ph.D., will make a presentation on two of the Company's novel anticancer compounds, AEZS-108 and AEZS-129, at Bio Partnering North America on Monday, February 28, 2011, at 4 p.m. (Pacific Time) in the West Meeting Room 218, of the Vancouver Convention Center in Vancouver, Canada.

AEZS-108, the LHRH targeted cytotoxic peptide conjugate composed of a peptide carrier and a cytotoxic agent (doxorubicin), has successfully completed a Phase 2 program in advanced ovarian and advanced endometrial cancer. This compound is also currently in Phase 1/2 trials in refractory prostate cancer and bladder cancer. AEZS-129, an orally-active PI3K inhibitor compound, is in preclinical development in oncology.

Furthermore, Company President and CEO, Juergen Engel, Ph.D., will take part in a panel discussion on novel cancer treatments at the upcoming RBC Capital Markets Healthcare Conference. The panel discussion entitled, "Cancer Treatments: Under the Radar Unique Late-Stage Opportunities", will take place on Wednesday, March 2, 2011, at 9 a.m. (Eastern Time) in the Holmes I Room of the New York Palace Hotel, in New York City.